NUIX LIMITED (NXL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NXL

NXL - NUIX LIMITED

FNArena Sector : Software & Services
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: 0.15
Index: ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Nuix is an Australian technology company providing investigative analytics and intelligence software for transforming large amounts of data into actionable intelligence. The company listed in December 2020.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.25

21 Mar
2025

-0.140

OPEN

$3.37

-4.13%

HIGH

$3.46

7,476,347

LOW

$3.24

TARGET
$5.70

+0.20 change from previous day

 75.4% upside
OTHER COMPANIES IN THE SAME SECTOR
360 . AHI . ALC . AMX . ATA . BMT . COS . DOC . EVS . GTK . KYP . NET . QOR . RDY . SKO . UBN . VGL . XF1 . YOJ . Z2U .
FNARENA'S MARKET CONSENSUS FORECASTS
NXL: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 1.6 2.8 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A 80.6% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 116.1 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx1.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx220.6 M
Book Value Per Share xxxxxxxxxxxxxxx88.6
Net Operating Cash Flow xxxxxxxxxxxxxxx50.3 M
Net Profit Margin xxxxxxxxxxxxxxx2.28 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx1.80 %
Return on Invested Capital xxxxxxxxxxxxxxx1.76 %
Return on Assets xxxxxxxxxxxxxxx1.16 %
Return on Equity xxxxxxxxxxxxxxx1.80 %
Return on Total Capital xxxxxxxxxxxxxxx5.85 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx49.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx7 M
Total Debt xxxxxxxxxxxxxxx10 M
Goodwill - Gross xxxxxxxxxxxxxxx22 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx38 M
Price To Book Value xxxxxxxxxxxxxxx3.48

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx33.1 M
Capex % of Sales xxxxxxxxxxxxxxx15.00 %
Cost of Goods Sold xxxxxxxxxxxxxxx71 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx132 M
Research & Development xxxxxxxxxxxxxxx19 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Shaw and Partners

25/02/2025

1

Buy, High Risk

$5.70

75.38%

Nuix reported first-half FY25 results in line with Shaw and Partners' expectations, with management reaffirming full-year guidance and signalling a strong second half.

The company continues its transition towards a subscription-based model, driving higher recurring revenue and improved cash flow stability, explains the broker.

Management remains confident in its growth strategy, observes Shaw, with key pipeline opportunities in legal, regulatory, and corporate compliance markets.

The analysts see significant upside potential as Nuix executes its strategic initiatives and scales its recurring revenue base.

The Buy, High Risk rating and $5.70 target are maintained.

FORECAST
Shaw and Partners forecasts a full year FY25 dividend of 0.00 cents and EPS of 2.80 cents.
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of 10.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Moelis

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Petra Capital

30/01/2025

1

Buy

$4.87

49.85%

Nuix reiterated its guidance for annual contract value (ACV) growth of 15% for FY25 but included a range of 11-16%. 

Petra Capital expects 1H25 result to demonstrate modest ACV growth of 8-9% and has lowered its FY25 growth estimate to 10.9% to be the lower end of the company's 11-16% range.

The broker's EBITDA forecasts fall on lower top-line revenue, lower gross profit and higher R&D expense versus capitalised. These detractors are offset by lower sales and distribution expenses, reflecting a more subdued sales environment.

On the positive side, the broker notes NEO sales run rate of 46 deals is running ahead of its estimate of 48 for FY25 but will make compositional ACV adjustments to its forecasts at the 1H25 result.

Target price cut to $4.87 from $7.20. Buy rating retained.

FORECAST
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.50 cents.
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of 4.70 cents.
Access Extra Coverage Research History >

NXL STOCK CHART

FNArena News on NXL

1
In Case You Missed It – BC Extra Upgrades & Downgrades – 07-03-25

Mar 07 2025 - Weekly Reports
2
Australian Broker Call *Extra* Edition – Mar 03, 2025

Mar 03 2025 - Daily Market Reports
3
FNArena Corporate Results Monitor – 25-02-2025

Feb 25 2025 - Australia
4
Australian Broker Call *Extra* Edition – Jan 30, 2025

Jan 30 2025 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Jan 29, 2025

Jan 29 2025 - Daily Market Reports

Latest Software & Services News

1
The GenAI Arms Race Is Just Getting Started

Mar 19 2025 - International
2
Pro Medicus’ Valuation Predicament

Feb 19 2025 - Australia
3
DeepSeek Fuels AI Technology Advances

Feb 06 2025 - Feature Stories
4
DeepSeek & More AI Excitement For 2025

Jan 28 2025 - Feature Stories
5
Xero: The Pause That Refreshes

Jan 23 2025 - Technicals
6
Pro Medicus, A Global Software Super Star

Dec 19 2024 - Australia
7
Higher Margins Underpin Gentrack’s Ambitions

Nov 28 2024 - Small Caps
8
Targets Jump For Embattled WiseTech

Nov 28 2024 - Australia
9
Nuix Rises From The Ashes

Nov 08 2024 - Small Caps
10
WiseTech In Global Supply Chain Sweet Spot

Oct 10 2024 - Australia